Research And Markets - Pharmaceutical Thought Leaders Benefit Every Pharmaceutical Company, From Industry Leaders To Start-Up Biotechnology Firms

Research and Markets (researchandmarkets.com/reports/c9382) has announced the addition of Pharmaceutical Thought Leaders: Brand Strategies and Product Positioning to their offering.

(PRWEB) November 29, 2004 -- Every pharmaceutical company, from industry leaders to start-up biotechnology firms, is involved in building, developing and benefiting from thought leader relationships. Many companies, however, suffer from industry-wide challenges in thought leader management -- challenges that create missed opportunities and result in lacklustre performance.

Research and Markets (http://www.researchandmarkets.com/reports/c9382) has announced the addition of Pharmaceutical Thought Leaders: Brand Strategies and Product Positioning to their offering.

Successful, long-term thought leader relationships are forged through a pharmaceutical companys ability to create mutually beneficial relationships with top opinion leader candidates. The most lucrative thought leader relationships are steeped in this scientific research that helps the company promote its treatments while allowing the physician to advance her interest -- and influence -- in a given area.

Companies that excel at developing thought leader programs with real impact do so by focusing on several strategic components:

- Investment -- The average brand allocates nearly $40 million to support thought leader activities throughout the development cycle.

- Relationship Management -- The most lucrative thought leader contacts are consistently managed and maintained by developing win-win relationships.

- Early Involvement -- In the last two years, more companies formally have formally launched their thought leader initiatives early in development, some before Phase I.

- Local Thought Leader Visibility -- Recently, local thought leader usage has been on the rise, indicating more market impact at lower costs across the industry.

The companies mentioned in this report are as follows:
AstraZeneca
Aventis
GlaxoSmithKline
Bristol-Myers Squibb
NPS Pharmaceuticals
3M Pharmaceutical
McNeil
Eli Lilly
Pfizer
Pharmacia
Sanofi-Synthelabo
Wyeth
Ingenix
Camelot-IDPro
Chrinoron Pharma
Isis Pharma

For more information visit http://www.researchandmarkets.com/reports/c9382

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###